Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer (NCT06787612)
Multi-Arm Phase 2 Platform Study of Ubamatamab (REGN4018; MUC16×CD3 Bispecific Antibody) With or Without Additional Agents in Platinum-Resistant Ovarian Cancer
🩺 Plain-English Summary (8th-Grade Level)
This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on participants who have advanced ovarian cancer. The aim of the study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other anti-cancer drugs (bevacizumab, cemiplimab, fianlimab, REGN10597 and a standard chemotherapy drug, pegylated liposomal doxorubicin \[PLD\]), referred to as "combination drugs'. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug and its experimental combinations * How much study drug and fianlimab is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects) and its combinations
Who can join: Review the eligibility criteria below.
Location: The University of Alabama at Birmingham — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (55 Sites)
Showing the first 25 of 55 sites.
- The University of Alabama at Birmingham — Birmingham, Alabama
- UC San Diego Health — La Jolla, California
- Cedars Sinai Medical Center — Los Angeles, California
- Mayo Clinic Jacksonville — Jacksonville, Florida
- University of Miami Sylvester Comprehensive Cancer Center — Miami, Florida
- Advent Health Cancer Institute — Orlando, Florida
- Tampa General Hospital Cancer Institute — Tampa, Florida
- University of Chicago — Chicago, Illinois
- The University of Kansas Cancer Center — Westwood, Kansas
- Norton Cancer Institute, St. Matthews Clinic — Louisville, Kentucky
- Massachusetts General Hospital — Boston, Massachusetts
- Karmanos Cancer Institute — Detroit, Michigan
- The Ohio State University Comprehensive Cancer Center — Hilliard, Ohio
- Providence Cancer Institute — Portland, Oregon
- University of Pittsburgh Medical Center, Magee-Womens Hospital — Pittsburgh, Pennsylvania
- West Penn Hospital of Allegheny Health Network — Pittsburgh, Pennsylvania
- Avera Cancer Institute Sioux Falls — Sioux Falls, South Dakota
- UT Southwestern Medical Center — Dallas, Texas
- Swedish Cancer Institute — Seattle, Washington
- University of Wisconsin — Madison, Wisconsin
- Medical College of Wisconsin — Milwaukee, Wisconsin
- CancerCare Manitoba — Winnipeg, Manitoba
- Princess Margaret Cancer Centre — Toronto, Ontario
- Centre de Santé et de Services Sociaux de la Montérégie-Centre — Greenfield Park, Quebec
- Jewish General Hospital — Montreal, Quebec
📞 Contact the Study Coordinator
Phone: (844) 734-6643
Email: clinicaltrials@regeneron.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Ovarian Cancer
- Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy — New York, New York
- Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer — Pittsburgh, Pennsylvania
- Trial on Radical Upfront Surgery in Advanced Ovarian Cancer — New York, New York
- Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) — Duarte, California
- Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) — Little Rock, Arkansas
- NeoVax With Nivolumab in Patients With Ovarian Cancer — Boston, Massachusetts
Explore by condition: All Ovarian Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.